Cryptococcosis is an invasive infection caused by yeast-like fungus of the genera Cryptococcus spp. The antifungal therapy for this disease provides some toxicity and the incidence of infections caused by resistant strains increased. Thus, we aimed to assess the consequences of fluconazole subdoses during the treatment of cryptococcosis in the murine inflammatory response and in the virulence factors of Cryptococcus gattii. Mice infected with Cryptococcus gattii were treated with subdoses of fluconazole. We determined the behavior of mice and type 1 interferon expression during the treatment; we also studied the virulence factors and susceptibility to fluconazole for the colonies recovered from the animals. A subdose of fluconazole prolonged the survival of mice, but the morbidity of cryptococcosis was higher in treated animals. These data were linked to the increase in: (i) fluconazole minimum inhibitory concentration, (ii) capsule size and (iii) melanization of C. gattii, which probably led to the increased expression of Medical Mycology, 2017, Vol. 55, No. 2 type I interferons in the brains of mice but not in the lungs. In conclusion, a subdose of fluconazole altered fungal virulence factors and susceptibility to this azole, leading to an altered inflammatory host response and increased morbidity.
Introduction
Cryptococcus gattii is the main etiological agent of cryptococcosis in immunocompetent individuals. 1 The infection is acquired after inhaled cryptococci penetrate lung tissue, reproduce, enter the bloodstream, and disseminate to other organs, often the central nervous system (CNS). 2, 3 The main virulence factors of this fungus are the polysaccharide (PS) capsule, melanin, and urease. 4 The PS capsule is antiphagocytic and serves as an antioxidant 5 ; its structure is highly variable and undergoes changes in size, charge, and rearrangements during infection. The treatment of cryptococcosis causes concern, due to drug side effects and the emergence of resistant fungal isolates to commonly used antimicrobials, for example, amphotericin B and fluconazole. [6] [7] [8] [9] [10] Specifically, the resistance of C. gattii to fluconazole can occur in vivo 11 and in vitro 12 by mutation and/or overexpression of the ERG11 gene, the overexpression of efflux pumps, alterations in enzymes of the pathway of ergosterol synthesis and decreased permeability of the plasma membrane to the drug. [13] [14] [15] Recently, it has been shown that the antifungal resistance in Cryptococcus may be entirely dependent on PDR11. 16 Sionov et al. 12 characterized the heteroresistance to fluconazole in a murine model and correlated this with increased fungal virulence 10 ; heteroresistant C. gattii to itraconazole also presented a high virulence profile. 17 However, little is known about the consequences of fluconazole sub-doses in cryptococosis, since the drug can act as a selective agent of more resistant microbial populations and can also alter fungal virulence factors. In this study, we investigated the effect of fluconazole subdoses in the murine response and on the virulence of C. gattii. The results suggested an altered expression of type I interferon, a reduced drug susceptibility, and higher C. gattii virulence when mice were treated with fluconazole subdoses.
Materials and Methods
Cryptococcus gattii, antifungal drug susceptibility testing and dose administered in mice
We tested the L27/01 strain of C. gattii from the culture collection of the Laboratório de Micologia/Universidade Federal de Minas Gerais, Brazil. The minimum inhibitory concentration (MIC) for fluconazole (Sigma-Aldrich, St. Louis, Missouri, USA) was determined by the microdilution method. 18, 19 Mice infected with C. gattii were treated with 10 mg/kg/day fluconazole, a current dose used in animal studies, which is equivalent to 50 mg/kg/day for the treatment of human cryptococcosis. 20 This concentration can be considered a drug subdose, since 200-400 mg/kg/day fluconazole is recommended for humans suffering from cryptococcosis.
21-23
Intratracheal infection, behavioral analysis, colony forming units and histopathology
Female 6-to 8-week-old C57BL/6 mice were used in all experiments. The animal studies were approved by the Comissão deÉtica no Uso de Animais (CEUA) from the Universidade Federal de Minas Gerais (Protocol 312/2012). Mice were provided with food and water ad libitum in a controlled environment with a 12-h light/dark photoperiod. Any mice that appeared moribund (e.g., intense piloerection, convulsions, lack of locomotor activity) were euthanized under anesthesia by cervical dislocation. Mice (n = 10/group) were anesthetized intraperitoneally (i.p.) with ketamine (60 mg/kg) and xylazine (10 mg/kg) and were then inoculated intratracheally (i.t.) with 30 μl L27/01 strain (1×10 6 CFU/animal) or PBS (control). Animals were monitored twice daily for survival. Fluconazole (10 mg/kg/day) was administered daily i.p., from 10 to 15 days post-infection (d.p.i.). The nontreated control group was administered with PBS. The SHIRPA protocol for the behavioral and functional assessment of neurological diseases was used. The tasks were grouped into five functional categories: neuropsychiatric state, motor behavior, autonomic function, muscle tone and strength, and reflex and sensory function. 24, 25 The mice were blinded, examined daily, and the score for each functional category was calculated as the total of the evaluated parameters 24, 25 using EpiData 3.1 software.
Other groups of mice were anesthetized i.p., infected, and euthanized to obtain lung and brain material at 15 d.p.i. Organ homogenates were plated on to Sabouraud Dextrose Agar, Difco Laboratories, Detroit, Michigan, USA(SDA), to determine the CFU per gram of tissue. The colonies recovered from nontreated mice were named L27/NT, and those recovered from treated animals were named L27/FLC. A mean of five colonies recovered from the lungs and Table 1 . Sequences of the primers used in this study for qPCR of genes from mice (IFN-α, IFN-β and MX2) and from C. gattii (MDR1, PDR11, ERG11, UXS1, and CAP59).
CGTACCCGTGGTCTGTTCAA TTGTCACGGAGTTCGTGGAG brain of each animal were used to determine the fluconazole MIC. The lungs and brain were also stained with hematoxylin-eosin (HE).
Extraction of RNA, reverse transcription and real-time PCR for organs and for C. gattii
The mRNA levels of interferon-α (IFN), IFN-β, and MX2 were determined for the lungs and brain from five animals for each group, whereas the levels of mRNA for the efflux pumps PDR11 and MDR1, the ergosterol enzyme ERG11, and the capsule genes CAP59 and UXS1 were determined in the five colonies recovered from the organs of each animals group. The RNA from lungs and brain was isolated using Trizol (Invitrogen), and RNA from L27/NT and L27/FLC strains was extracted using the RNeasy kit (Qiagen, Germany). The RNA concentration was assessed by Nanodrop (Thermo Fisher Scientific). The cDNA was prepared using MMLV (Promega, Madison, WI, USA) and oligo-dT (Qiagen, Germany). Real-time PCR (qPCR) was performed in a StepOne Real-Time PCR System (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystem, USA, 5 ml) as a reaction mix, supplemented with 200 nM of each primer and 1 μl cDNA template to a final volume of 10 μl. All experiments were performed using three independent cultures, and each cDNA sample was analyzed in triplicate for each primer pair. A melting curve analysis was performed at the end of the reaction to confirm the presence of a single PCR product. Data were normalized to actin cDNA amplified in each set of PCR experiments. Analyses were performed using the delta-delta Ct method. The primers used in these analyses are listed in Table 1 .
Phagocytosis assays
The J774.A1 murine macrophage (1×10 6 ) cells in DMEM supplemented with 10% FBS was seeded into 12-well culture plates and activated with 100 U/mL INF-γ (Sigma) and 500 ng/ml LPS (Sigma) for 18 h at 37
• C with 5% CO 2 .
Cryptococcus gattii cells were opsonized with anti-GXM antibody 18B7 (1 μg/ml) for 1 h at 37
• C, centrifuged, and the pellet was resuspended in 500 μl FITC solution (500 μg/ml) and incubated for 10 min at room temperature. The cells were washed several times with PBS and counted in a Neubauer Chamber. Then, 1×10 7 yeast cells/ml were added to the wells containing the macrophage, and these were incubated for 2 h at 37
• C with 5% CO 2 . The wells were then washed three times with PBS and treated with Trypan Blue (Sigma). The cells were collected by scraping and were analyzed with a Guava easyCyte Flow Cytometer (Merck Millipore) by measuring the green fluorescence of 5,000 events. 26 A second plate was incubated under identical conditions for 24 h to evaluate the antifungal activity. After incubation, the wells were washed three times with PBS, and the cells were lysed with sterile ice-cold water and subsequently plated onto YPD plates for CFU determination. The survival index was obtained by normalizing the CFU counts after 24 h of interaction to the fluorescence units obtained in the flow cytometric analysis following 2 h of interaction.
27
Melanization and laccase assay 
Statistical analysis
Statistical analysis of all data was performed using GraphPad Prism version 5.0 with P < .05 as the significance threshold. The survival curve was plotted using KaplanMeier analysis, and the results were analyzed using the Long Rank test. The SHIRPA data were analyzed with the Wilcoxon Rank-Sum Test. 25 The other results were analyzed by analysis of variance (ANOVA), the nonparametric Friedman test, and the Student t-test.
Results
A subdose of fluconazole prolongs the survival of mice but cause higher morbidity Treated mice survived longer than nontreated mice ( Figure 1A) . Furthermore, the treatment reduced the fungal burden in the lungs and the brain ( Figure 1B) . No difference was observed in the distribution of yeasts in the lung parenchyma in the histological analysis ( Figure 1C-F) , although foamy macrophages were more evident in the treated group. Indeed, the behavioral alterations were more prominent in the treated groups, which performed worse in the behavioral tests ( Figure 1G-K) . Only the neuropsychiatric state was equally altered in treated and nontreated groups ( Figure 1I ).
The expression of Type I IFNs is increased in the brain but not in the lungs of treated mice
The expression of type I IFN was different between the organs of the evaluated groups. The FLC group showed an increase in IFN levels in the brain and lungs compared to the NT group (Figure 2) . The data are expressed as the quotient of the test over the control. There was significant difference between the FLC and NT groups for IFN β in the lungs. However, expression was higher in the brain of treated mice compared to that in the NT group for IFN α and IFN β.
Cryptococcus gattii from treated mice was more internalized and had a higher intracellular proliferation rate
The C. gattii strain from treated mice (L27/FLC) was more phagocytosed ( Figure 3A ) and had an increased ability to survive within macrophages ( Figure 3B ) than the C. gattii strain from nontreated mice (L27/NT).
Subdoses of fluconazole lead to an increase in the minimum inhibitory concentration
The MICs of fluconazole based on the percentage of colonies recovered from treated and nontreated groups of mice are shown in Figure 4 . The MICs of fluconazole against the L27 strain before infection varied from 8.0 to 16.0 mg/l. After intratracheal infection, the MIC for the L27/NT strain was 16-32 mg/l, both in the lungs and the brain ( Figure 4A-B) . The MIC of fluconazole against the L27/FLC strain was higher in both organs ( Figure 4A -B), reaching 256 mg/l.
Subdoses of fluconazole increase the capsule size and melanization of C. gattii
To assess whether subdoses of fluconazole affect some virulence factors, we evaluated the levels of laccase activity and capsule size ( Figure 5 ). There was no difference in fungal growth at 37 • C (data not shown); however, laccase activity and melanization were significantly higher in yeasts from treated animals ( Figure 5A-B) . The capsule size was also significantly higher in L27/FLC, either from the brain or lungs ( Figure 5C -E).
Fungal gene expression differs depending on whether C. gattii is recovered from the lungs or the brain
Overall, colonies recovered from the lungs of infected mice exhibited significantly higher gene expression than the control strain, whereas the strains recovered from the brain showed reduced gene expression compared to the control ( Figure 6 ). In the lungs (Figure 6A ), the expression of UXS1 and CAP59 was higher in L27/NT colonies, suggesting that the fungus might attempt to compensate for the diminished capsule size. There was no difference between PDR11, MDR1, and ERG11 in the colonies recovered from the lungs. Notably, the expression of MDR1, ERG11, and UXS1 in colonies recovered from the brain was higher in colonies of L27NT, whereas CAP59 expression was higher in colonies recovered from treated mice (L27/FLC) ( Figure 6B ).
Correlations between the studied genes
We verified intriguing correlations between some studied genes, both from the fungus and from mice. Regarding gene expression in the yeast, we verified strong positive correlations between ERG11 and MDR1 (R 2 = 0.97, P = .004) in the NT group; CAP59 and UXS1 (R 2 = 0.99, P = .002);
CAP59 and MDR1 (R 2 = 0.98, P = .014); and UXS1 and MDR1 (R 2 = 0.98, P = .03) in the treated group. These 
Discussion
Several factors can interfere in the efficacy of antifungal agents, including drug absorption, adherence to treatment, reinfection, immunity deficiency, drug resistance and subtherapeutic doses. 29 Insufficient quantities of drug delivery can lead to clinical relapses that might erroneously be confused with drug resistance or reinfection and cause a fatal outcome for a patient. 30 The treatment with 10 mg/kg/day fluconazole, a subtherapeutic dose for mice, increased the survival of animals and reduced the fungal burden in the brain but was not able to reduce the burden in the lungs. The more rapid death of untreated animals might be due to the higher fungal burden in the brain, causing severe meningoencephalitis. Previously, it was established that the survival of animals was dependent on the fungal burden. 31 Despite the increased survival of the treated animals, they appeared more moribund than untreated mice, as assessed by the behavioral analysis. This might be due to the influence of fluconazole subdoses on the virulence factors of yeast and on the inflammatory response of the host, which showed areas of granulomatous infiltrate, which is a common finding in immunocompetent hosts infected with Cryptococcus gattii. 32, 33 The neuropsychiatric state category was affected in both groups and might indicate cerebral damage caused by the fungus. 34 Indeed, the treated group showed an increased expression of type I IFN. Recent data demonstrated that the induction of type I IFN dramatically improves host resistance against the etiologic agents of cryptococcosis by beneficial alterations in both innate and adaptive immune responses. 35 In addition, it was demonstrated that type I IFN induction combined with fluconazole resulted in a synergistic antifungal effect that is reflected in a reduction in the fungal burden. 35 This fact can be easily associated with our data on the fungal burden but also explains the higher inflammation and, consequently, the increased morbidity when animals were exposed to subdoses of fluconazole, since this might disorganize the cell structure and modify the fungal PS capsule 12 and cell wall, culminating in altered antigen presentation and cytokine production. Indeed, fluconazole led to the recovery of colonies with a lower susceptibility to this drug, which might be explained by the fact that Cryptococcus can undergo genetic changes in vivo by establishing a means to evade the host's defenses and antifungals. 36, 37 The cryptococcal interactions with phagocytes allow the pathogen to survive intracellularly and to disseminate to the central nervous system and escape. 38 Therefore, it is important to evaluate whether the cryptococcal strains recovered from two groups of infected mice react differently to macrophages. Similar to the situation in vitro, 12 C. gattii was more internalized by phagocytes in the presence of fluconazole. Notably, we confirmed important changes in the yeast virulence factors when they were recovered from treated mice. Virulence structures allow the fungus to overcome the host defense system and cause a disease with a worse prognosis. Although fluconazole decreases the capsule and laccase activity in vitro, during the murine infection model, the capsule increases in size, and the laccase activity and melanization are considerably higher. The synthesis of the PS capsule of Cryptococcus is complex and requires many intermediates. 39 Many of these intermediates are encoded by the CAP genes, which are essential for virulence. The treated animals showed an increased expression of CAP59, and yeast recovered from this group possessed larger capsules. Altogether, these virulence factors might be responsible for the increased morbidity of the treated animals.
Cryptococcus gattii has a high potential to develop resistance to fluconazole in vitro, [8] [9] [10] 40 and the expulsion of the drug from the yeast is one of the mechanisms involved in this resistance, 41 together with mutations or overexpression of the ERG11 gene. Fungal genomes harbor numerous ABC (ATP-binding cassette) proteins located in various cellular compartments, which confer resistance to a wide variety of drugs. Two Cryptococcus ABC transporters have been experimentally characterized: MDR1 and PDR11, and these are often responsible for the resistance to the azoles in Cryptococcus spp. 16, 42 Our in vivo results demonstrated that the differences in the expression of these genes depend on the site from where the yeast is recovered, since gene expression from L27/FLC colonies was higher in the lung, whereas colonies in the brain had a lower gene expression. Notably, the expression of MDR1 and ERG11 was higher in L27/NT recovered from the brain, providing another perspective on the role of these membrane transporters during the fungus-host interaction. This difference in gene expression according to the yeast site occurred for all C. gattii genes studied, except for the UXS1 gene. These data suggest that these genes might not be exclusively involved in the resistance of C. gattii to fluconazole and might also be influenced by the host microenvironment and its particular milieu of inflammatory mediators, which determines the profile of the disease caused by the fungus. Considering that fluconazole is aneuploidogenic, 43 our previous work with the same strain tested here revealed no influence of this antifungal in the banding patterns generated by the pulsed field gel electrophoresis (PFGE) technique. 12 The statistical correlation between fungal and mice genes revealed that the increase in type I IFN expression correlates with the decrease in ERG11, resulting in fungal ergosterol biosynthesis. It is possible to speculate that the synergistic action between fluconazole and type I IFN helped the host to contain the infection within the lung, causing a decrease in ERG11 expression, to maintain fluconazole inside the cell and to avoid dissemination of the yeast. Considering only fungal gene expression, yeasts recovered from treated animals showed a strong positive association between CAP59 and UXS1. These genes together are responsible for the increased capsule size, since this association was not found in strains with smaller capsules. Moreover, the CAP59/UXS1 genes positively correlated with efflux pump genes, which validate the fact that therapy with subdoses of fluconazole can affect important virulence factors of the fungus.
In conclusion, we provide new insights concerning the treatment of cryptococcosis with fluconazole and demonstrate that a subdose can influence the virulence factors of the fungus and the inflammatory response of the host.
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